Scale/item | Treatment period 1 | |||||
---|---|---|---|---|---|---|
Pre-dose | Nurse visit 2 | End of Tx | ||||
N | M (SD) | N | M (SD) | N | M (SD) | |
2 FS (range = 2–10) | 12 | 5.42 (0.98) | 12 | 4.11 (1.21) | 12 | 4.22 (1.04) |
3 FS (range = 3–15) | 12 | 8.0 (1.35) | 12 | 6.09 (1.95) | 12 | 6.26 (1.69) |
4 FS (range = 4–20) | 12 | 9.96 (1.65) | 12 | 7.60 (2.44) | 12 | 7.96 (2.14) |
5MS (range = 5–25) | 12 | 11.84 (1.76) | 12 | 9.27 (2.61) | 12 | 9.85 (2.64) |
Item 1: tiredness at rest (range = 1–5) | 12 | 2.58 (0.84) | 12 | 1.98 (0.85) | 12 | 2.04 (0.83) |
Item 2: tiredness during activity (range = 1–5) | 12 | 2.85 (0.64) | 12 | 2.17 (0.81) | 12 | 2.25 (0.58) |
Item 3: muscle weakness at rest (range = 1–5) | 12 | 1.96 (0.48) | 12 | 1.52 (0.51) | 12 | 1.70 (0.62) |
Item 4: muscle weakness during activity (range = 1–5) | 12 | 2.57 (0.49) | 12 | 1.94 (0.51) | 12 | 1.97 (0.59) |
Item 5: muscle pain at rest (range = 1–5) | 12 | 1.67 (0.52) | 12 | 1.47 (0.59) | 12 | 1.69 (0.63) |
Scale/item | Treatment period 2 | |||||
---|---|---|---|---|---|---|
Pre-dose | Nurse visit 2 | End of Tx | ||||
N | M (SD) | N | M (SD) | N | M (SD) | |
2 FS (range = 2–10) | 12 | 4.73 (1.09) | 11 | 4.39 (1.24) | 11 | 4.20 (1.29) |
3 FS (range = 3–15) | 12 | 7.10 (1.85) | 11 | 6.65 (1.85) | 11 | 6.28 (2.02) |
4 FS (range = 4–20) | 12 | 8.94 (2.21) | 11 | 8.26 (2.24) | 11 | 7.78 (2.35) |
5MS (range = 5–25) | 12 | 11.20 (2.66) | 11 | 10.13 (2.71) | 11 | 9.54 (3.03) |
Item 1: tiredness at rest (range = 1–5) | 12 | 2.38 (0.96) | 11 | 2.26 (0.94) | 11 | 2.08 (0.99) |
Item 2: tiredness during activity (range = 1–5) | 12 | 2.57 (0.83) | 11 | 2.47 (0.99) | 11 | 2.23 (0.90) |
Item 3: muscle weakness at rest (range = 1–5) | 12 | 1.83 (0.64) | 11 | 1.61 (0.69) | 11 | 1.50 (0.48) |
Item 4: muscle weakness during activity (range = 1–5) | 12 | 2.15 (0.52) | 11 | 1.92 (0.58) | 11 | 1.97 (0.70) |
Item 5: muscle pain at rest (range = 1 to 5) | 12 | 1.94 (0.74) | 11 | 1.61 (0.67) | 11 | 1.50 (0.58) |